Physician profile
Jerry Liu
NPI 1003375296
$1,248.86
in general payments reported to CMS, 2019-2025
12 companies · $1,027 in 2025
The $1,027 reported for 2025 was more than what 79% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $222 · 2025: $1,027.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,248.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $227.80 | 2024-2025 | Dovato, Cabenuva |
| Abbvie INC. | $205.23 | 2024-2025 | |
| Gilead Sciences, INC. | $194.69 | 2024-2025 | |
| Melinta Therapeutics, LLC | $146.41 | 2025 | Rezzayo, Kimyrsa, Orbactiv |
| Paratek Pharmaceuticals, INC. | $127.39 | 2024-2025 | Nuzyra |
| Cumberland Pharmaceuticals, INC. | $93.12 | 2025 | Vibativ |
| Insmed, INC. | $87.24 | 2024-2025 | Arikayce |
| Invivyd INC | $41.55 | 2024-2025 | Pemgarda |
| Merck Sharp & Dohme LLC | $39.70 | 2024-2025 | Prevymis, Zerbaxa, Dificid |
| Shionogi INC | $30.65 | 2025 | Fetroja |
| Ferring Pharmaceuticals INC. | $27.68 | 2024 | Rebyota |
| Octapharma USA, INC. | $27.40 | 2024 | Panzyga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.